ReviewCell death & disease2025
HypoxamiRs: the hidden architects of tissue adaptation in hypoxia.
Review in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Paternal heat conditioning enhances offspring's thermal resilience via epigenetic regulation of mir-210a.Scientific reports · 2026Article
- Next-Generation Metabolic Reprogramming in iPSC-Derived Cardiomyocytes: CRISPR-EV Synergy for Precision Cardiac Regeneration.Biomolecules · 2026Review
- Non-coding RNA biomarkers in resistant hypertension: a scoping review.Frontiers in molecular biosciences · 2026Review
- Hypoxic adaptation theory of cancer.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia, or reduced oxygen availability, triggers a spectrum of adaptive responses across tissues, including angiogenesis, metabolic reprogramming, and modulation of survival pathways. Central to these adaptations are hypoxia-regulated microRNAs (miRNAs), hypoxamiRs, which fine-tune gene expression in a context-dependent manner. HypoxamiRs are transcriptionally regulated by hypoxia-inducible factors (HIFs), tissue-specific transcriptional programs, and microenvironmental cues, enabling precise responses to hypoxia. HypoxamiRs exhibit distinct expression profiles across tissues, reflecting their specialized roles. In ischemic tissue, they activate angiogenic and cytoprotective programs, while in metabolically active or malignant tissues, they rewire energy production and promote survival. This tissue specificity underlies their dual function as both regulators of physiological adaptation and drivers of pathology in chronic hypoxia. Increasingly, hypoxamiRs are being recognized as non-invasive biomarkers and therapeutic targets in diseases such as cancer, cardiovascular disorders, and fibrosis. Compared to canonical hypoxia pathways, hypoxamiRs offer a versatile and finely tunable layer of regulation. This review presents a unified framework in which hypoxamiRs emerge not merely as downstream effectors of HIF signaling but as integrative architects at the intersection of oxygen sensing, epigenetic remodeling, and cellular identity. Their coordinated regulatory functions make them promising tools for precision medicine in hypoxia-related diseases. Understanding how hypoxamiRs operate across tissues and pathologies may unlock new diagnostic and therapeutic strategies for complex, oxygen-sensitive conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.